BRPI0413062A - compostos de sulfonamida, processos de obtenção de seus derivados, seus medicamentos e usos - Google Patents
compostos de sulfonamida, processos de obtenção de seus derivados, seus medicamentos e usosInfo
- Publication number
- BRPI0413062A BRPI0413062A BRPI0413062-6A BRPI0413062A BRPI0413062A BR PI0413062 A BRPI0413062 A BR PI0413062A BR PI0413062 A BRPI0413062 A BR PI0413062A BR PI0413062 A BRPI0413062 A BR PI0413062A
- Authority
- BR
- Brazil
- Prior art keywords
- processes
- derivatives
- obtaining
- mixture
- medicines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/40—Nitrogen atoms, not forming part of a nitro radical, e.g. isatin semicarbazone
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Psychology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Child & Adolescent Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
"COMPOSTOS DE SULFONAMIDA, PROCESSOS DE OBTENçãO DE SEUS DERIVADOS, SEUS MEDICAMENTOS E USOS". A presente invenção se refere a novos derivados de sulfonamida da fórmula geral (Ia, Ib, Ic) , (I), (I a, I b, I c) , opcionalmente na forma de seus estereoisómeros, de preferência enantiómeros ou diastereómeros, sua mistura racêmica ou na forma de uma mistura de pelo menos dois de seus estereoisómeros, de preferência enantiómeros ou diastereómeros, em qualquer proporção de mistura, ou seus sais, de preferência seus sais fisiologicamente aceitáveis correspondentes ou solvatos correspondentes; a processos para seu preparo, à sua aplicação como medicamentos em produtos terapêuticos humanos e/ou veterinários e à composições farmacêuticas contendo os mesmos. Os novos compostos da presente invenção podem ser usados na indústria farmacêutica como intermediários e para o preparo de medicamentos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200301806A ES2222828B1 (es) | 2003-07-30 | 2003-07-30 | Derivados de 1-sulfonilindoles, su preparacion y su aplicacion como medicamentos. |
PCT/EP2004/008516 WO2005013974A1 (en) | 2003-07-30 | 2004-07-29 | 1-sulfonylindole derivatives, their preparation and their use as 5-ht6 ligands |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0413062A true BRPI0413062A (pt) | 2006-10-17 |
Family
ID=34130540
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0413062-6A BRPI0413062A (pt) | 2003-07-30 | 2004-07-29 | compostos de sulfonamida, processos de obtenção de seus derivados, seus medicamentos e usos |
Country Status (21)
Country | Link |
---|---|
US (1) | US7655690B2 (pt) |
EP (1) | EP1648443B1 (pt) |
JP (1) | JP2007500168A (pt) |
KR (1) | KR20060056347A (pt) |
CN (1) | CN1863527A (pt) |
AR (1) | AR045159A1 (pt) |
AT (1) | ATE473738T1 (pt) |
AU (1) | AU2004262490A1 (pt) |
BR (1) | BRPI0413062A (pt) |
CA (1) | CA2533996A1 (pt) |
DE (1) | DE602004028125D1 (pt) |
EC (1) | ECSP066330A (pt) |
ES (2) | ES2222828B1 (pt) |
IL (1) | IL172956A0 (pt) |
MX (1) | MXPA06001229A (pt) |
NO (1) | NO20060342L (pt) |
PE (1) | PE20050726A1 (pt) |
RU (1) | RU2006105782A (pt) |
TW (1) | TW200509908A (pt) |
WO (1) | WO2005013974A1 (pt) |
ZA (1) | ZA200600427B (pt) |
Families Citing this family (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2246721B1 (es) * | 2004-08-10 | 2007-03-16 | Laboratorios Del Dr. Esteve, S.A. | Compuestos indolicos sustituidos, su preparacion y su uso como medicamentos. |
EP1632491A1 (en) * | 2004-08-30 | 2006-03-08 | Laboratorios Del Dr. Esteve, S.A. | Substituted indole compounds and their use as 5-HT6 receptor modulators |
PL1883451T3 (pl) | 2005-04-13 | 2011-05-31 | Neuraxon Inc | Podstawione związki indolowe mające aktywność hamowania NOS |
CA2637531A1 (en) | 2006-02-17 | 2007-08-30 | Memory Pharmaceuticals Corporation | Compounds having 5-ht6 receptor affinity |
ZA200809659B (en) | 2006-04-13 | 2010-03-31 | Neuraxon Inc | 1,5 and 3,6-substituted indole compounds having NOS inhibitory activity |
WO2007138611A1 (en) * | 2006-05-30 | 2007-12-06 | Suven Life Sciences Limited | 3-(heterocyclyl)-n-(arylsulfonyl)indole derivatives as functional 5-ht6 ligands |
BRPI0712898A2 (pt) * | 2006-07-03 | 2013-01-08 | Biovitrum Ab | indàis como moduladores de 5-ht6 |
ATE491685T1 (de) * | 2007-01-08 | 2011-01-15 | Suven Life Sciences Ltd | 5-(heterocyclyl)alkyl-n- (arylsulfonyl)indolverbindungen und ihre verwendung als 5-ht6-liganden |
EP1947085A1 (en) * | 2007-01-19 | 2008-07-23 | Laboratorios del Dr. Esteve S.A. | Substituted indole sulfonamide compounds, their preparation and use as medicaments |
DK2155674T3 (da) | 2007-05-03 | 2011-09-26 | Suven Life Sciences Ltd | Aminoalkoxy-aryl-sulfonamidforbindelser og anvendelse heraf som 5-HT6-ligander |
DE602007012683D1 (de) * | 2007-07-19 | 2011-04-07 | Esteve Labor Dr | Substituierte Tetrahydro-Chinolinsulfonamidverbindungen, ihre Herstellung und ihre Verwendung als Medikamente |
EP2018861A1 (en) * | 2007-07-26 | 2009-01-28 | Laboratorios del Dr. Esteve S.A. | 5HT6-Ligands such as sulfonamide derivatives in drug-induced weight-gain |
ATE495737T1 (de) | 2007-08-01 | 2011-02-15 | Esteve Labor Dr | Kombination von mindestens zwei 5-ht6-liganden |
MX356032B (es) | 2007-11-16 | 2018-04-11 | Neuraxon Inc | Compuestos indola y métodos para tratar el dolor visceral. |
MX2011002884A (es) | 2008-09-17 | 2011-04-21 | Suven Life Sciences Ltd | Compuestos de aril-sulfonamida-amina y su uso como ligandos de 5-ht6. |
US8318725B2 (en) | 2008-09-17 | 2012-11-27 | Suven Life Sciences Limited | Aryl indolyl sulfonamide compounds and their use as 5-HT6 ligands |
CN104276993B (zh) * | 2013-07-12 | 2019-03-15 | 广东东阳光药业有限公司 | 吲哚衍生物及其在药物上的应用 |
AU2015286049B2 (en) | 2014-07-08 | 2018-03-01 | Sunshine Lake Pharma Co., Ltd. | Aromatic heterocyclic derivatives and pharmaceutical applications thereof |
CN104529866A (zh) * | 2014-12-12 | 2015-04-22 | 广东东阳光药业有限公司 | 吲哚类衍生物及其在药物上的应用 |
US20190336585A1 (en) * | 2018-05-03 | 2019-11-07 | John Lawrence Mee | Method for sustainable human cognitive enhancement |
US20190390193A1 (en) * | 2018-06-23 | 2019-12-26 | John Lawrence Mee | Reversible method for sustainable human cognitive enhancement |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5120749A (en) * | 1991-02-20 | 1992-06-09 | Abbott Laboratories | Platelet activating antagonists |
GB9820113D0 (en) * | 1998-09-15 | 1998-11-11 | Merck Sharp & Dohme | Therapeutic agents |
CA2382247C (en) | 1999-08-12 | 2010-09-28 | Nps Allelix Corp. | Azaindoles having serotonin receptor affinity |
DE60119982T2 (de) * | 2000-12-22 | 2006-12-21 | Wyeth | Heterozyklylalkylindole oder -azaindole als 5-hydroxytryptamine-6 liganden |
HUP0400684A2 (hu) | 2000-12-22 | 2004-07-28 | Wyeth | 5-Hidroxitriptamin-6-ligandumként használható heterociklilindazol- és -azaindazol-származékok, előállításuk és ezeket tartalmazó gyógyszerkészítmények |
CA2433351A1 (en) | 2001-01-30 | 2002-08-08 | Eli Lilly And Company | Benzenesulfonic acid indol-5-yl esters as antagonists of the 5-ht6 receptor |
DK1438045T3 (da) * | 2001-10-23 | 2007-06-11 | Biovitrum Ab | Anvendelse af indol- og indolin-derivater ved behandling af obesitet eller til reduktion af födeindtag |
TW200301251A (en) * | 2001-12-20 | 2003-07-01 | Wyeth Corp | Azaindolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands |
-
2003
- 2003-07-30 ES ES200301806A patent/ES2222828B1/es not_active Expired - Fee Related
-
2004
- 2004-07-29 AT AT04763613T patent/ATE473738T1/de not_active IP Right Cessation
- 2004-07-29 AU AU2004262490A patent/AU2004262490A1/en not_active Abandoned
- 2004-07-29 CA CA002533996A patent/CA2533996A1/en not_active Abandoned
- 2004-07-29 DE DE602004028125T patent/DE602004028125D1/de active Active
- 2004-07-29 AR ARP040102701A patent/AR045159A1/es unknown
- 2004-07-29 KR KR1020067001740A patent/KR20060056347A/ko not_active Application Discontinuation
- 2004-07-29 ZA ZA200600427A patent/ZA200600427B/en unknown
- 2004-07-29 RU RU2006105782/04A patent/RU2006105782A/ru unknown
- 2004-07-29 TW TW093122676A patent/TW200509908A/zh unknown
- 2004-07-29 EP EP04763613A patent/EP1648443B1/en active Active
- 2004-07-29 MX MXPA06001229A patent/MXPA06001229A/es active IP Right Grant
- 2004-07-29 US US10/566,400 patent/US7655690B2/en not_active Expired - Fee Related
- 2004-07-29 BR BRPI0413062-6A patent/BRPI0413062A/pt not_active IP Right Cessation
- 2004-07-29 WO PCT/EP2004/008516 patent/WO2005013974A1/en active Application Filing
- 2004-07-29 ES ES04763613T patent/ES2348621T3/es active Active
- 2004-07-29 CN CNA2004800280717A patent/CN1863527A/zh active Pending
- 2004-07-29 JP JP2006521532A patent/JP2007500168A/ja active Pending
- 2004-08-02 PE PE2004000739A patent/PE20050726A1/es not_active Application Discontinuation
-
2006
- 2006-01-02 IL IL172956A patent/IL172956A0/en unknown
- 2006-01-23 NO NO20060342A patent/NO20060342L/no not_active Application Discontinuation
- 2006-01-30 EC EC2006006330A patent/ECSP066330A/es unknown
Also Published As
Publication number | Publication date |
---|---|
WO2005013974A1 (en) | 2005-02-17 |
NO20060342L (no) | 2006-01-23 |
ES2222828A1 (es) | 2005-02-01 |
ATE473738T1 (de) | 2010-07-15 |
CA2533996A1 (en) | 2005-02-17 |
TW200509908A (en) | 2005-03-16 |
EP1648443A1 (en) | 2006-04-26 |
EP1648443B1 (en) | 2010-07-14 |
CN1863527A (zh) | 2006-11-15 |
KR20060056347A (ko) | 2006-05-24 |
PE20050726A1 (es) | 2005-11-16 |
US20070060581A1 (en) | 2007-03-15 |
IL172956A0 (en) | 2006-06-11 |
RU2006105782A (ru) | 2007-09-20 |
DE602004028125D1 (de) | 2010-08-26 |
ZA200600427B (en) | 2007-03-28 |
ES2348621T3 (es) | 2010-12-09 |
MXPA06001229A (es) | 2006-05-15 |
ES2222828B1 (es) | 2006-04-16 |
AR045159A1 (es) | 2005-10-19 |
AU2004262490A1 (en) | 2005-02-17 |
ECSP066330A (es) | 2006-08-30 |
US7655690B2 (en) | 2010-02-02 |
JP2007500168A (ja) | 2007-01-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0413062A (pt) | compostos de sulfonamida, processos de obtenção de seus derivados, seus medicamentos e usos | |
BRPI0413112A (pt) | compostos de indol-6 sulfonamida, processos de obtenção de seus derivados, seus medicamentos e usos como moduladores de 5-ht-6 | |
BR0214243A (pt) | Derivado de sulfonamida processo para a preparação de um derivado de sulfonamida e seus sais fisiologicamente aceitáveis, composição farmacêutica e uso de um derivado de sulfonamida | |
LV12632A (lv) | Pyrazoline derivatives their preparation and application as medicaments | |
ATE381535T1 (de) | Phenethanolaminderivate | |
BR0315720A (pt) | Composto, método para a profilaxia ou tratamento de uma condição clìnica em um mamìmefero, formulação farmacêutica, combinação, uso de um composto, processo para a preparação de um composto, e, intermediário | |
BRPI0510770A (pt) | derivados de fluorglicosìdeos de pirazóis, medicamentos contendo esses compostos e seu uso | |
AR028988A1 (es) | Derivados amida, proceso para su preparacion, composicion farmaceutica que los comprende, y su uso en la fabricacion de un medicamento util en el tratamiento de enfermedades o afecciones clinicas mediadas por citoquinas | |
AU2003298094A8 (en) | Medicinal arylethanolamine compounds | |
BR0313790A (pt) | Compostos de amida de ácido carboxìlico com efeito antagonista mch, medicamentos contendo estes compostos e processos para sua preparação | |
BR0207910A (pt) | HidantÈnios e sua utilização no tratamento do diabetes | |
UA92181C2 (ru) | Производные пиримидина и их применение в терапии и в производстве лекарственного средства для предотвращения и/или лечения болезни альцгеймера | |
BRPI0413110A (pt) | derivados de indo-5-il sulfonamida, sua preparação e uso de 5-ht-6 como moduladores | |
ES2579857T3 (es) | Composiciones de plasma rico en plaquetas | |
AR020662A1 (es) | Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento. | |
NO20060155L (no) | Indol-4-sulfonamid derivater, deres fremstilling og deres anvendelse 5-HT-6 som modulatorer | |
ATE450535T1 (de) | Neues verfahren zur herstellung von pleuromutilinderivaten | |
BR9910179A (pt) | Composto, composição farmacêutica, uso de um composto, e, processo para tratar uma doença ou condição mediada por fator xa em um animal de sangue quente | |
BRPI0410189A (pt) | uso de derivados de sulfonamida para a manufatura de um medicamento para a profilaxia e/ou tratamento de distúrbios relacionados com a ingestão de alimentos | |
BR112018073743A2 (pt) | composto, processo, método para tratamento de infecção bacteriana em um sujeito, uso de um composto, e composições farmacêuticas | |
BRPI0413001A (pt) | compostos de sulfonamida, processos de obtenção de seus derivados, medicamentos e usos como moduladores de 5-ht-6 | |
BR0318533A (pt) | azolidinacarbonitrilas e seu uso como inibidores de dpp-iv | |
BRPI0413101A (pt) | compostos de sulfonamida derivado de benzoxazinona, sua preparação e uso como medicamentos | |
BRPI0408441A (pt) | 2-(butil-1-sulfonilamino)-n-[1(r)-(6-metóxi-piridin-3-il)-p ropil]-benzamida, seu emprego como medicamento, assim como preparados farmacêuticos contendo-os | |
BR0115506A (pt) | Composições farmacêuticas tendo uma ação antidiabética, e processo para sua preparação |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012. |